An insight into Ceftazidime-avibactam activity on Carbapenem-resistant Enterobacterales causing bloodstream infections
Journal of Research in Clinical Medicine · 07.04.2026 · 14 · 34779
DOI: 10.34172/jrcm.026.34799 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Research in Clinical Medicine, online erschienen am 07.04.2026. Verfasst von Ekadashi Rajni und 2 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben.
Abstract (Originalsprache)
Introduction
Carbapenem-resistant Enterobacterales (CRE) are among the biggest challenges faced by the healthcare community worldwide. Antibiotic treatment of these infections remains challenging, especially in developing nations. Ceftazidime-avibactam (CZA) is a β-lactam-β-lactamase inhibitor combination with potent activity against CRE. The present study was conducted to provide insight into the in vitro activity of CZA against CRE causing bloodstream infections.
Methods
This was a prospective observational study, conducted from July 2022 to June 2023 at a tertiary care teaching hospital, Jaipur, and included all non-duplicate CRE isolates obtained from bloodstream infections in adult patients admitted to the ICU. Identification and antimicrobial susceptibility testing were performed using the VITEK-2 automated system and interpreted according to Clinical and Laboratory Standards Institute guidelines. All CRE isolates resistant to CZA were further tested for synergy between Ceftazidime-avibactam and Aztreonam (AT) using the disk elution method.
Results
During the one-year study period, 104 CRE strains were isolated in the laboratory from bloodstream infections in adult patients admitted to the ICU, which included 19 (18%) E. coli, 80 (77%) K.pneumoniae and 5 (5%) Enterobacter spp. Susceptibility rates of 61%, 31% and, 30% were observed for amikacin, tigecycline and minocycline, respectively. Overall, 31% and, 4% CRE isolates were susceptible to CZA and AT alone, respectively, while 97% were found to exhibit synergy.
Conclusion
In the present study, 69% CRE isolates were found to be resistant to CZA. CZA+ATM combination, however, demonstrated excellent in vitro activity against CRE isolated from blood cultures in our ICU setting. Thus, this combination can be considered a suitable therapeutic option in patients with sepsis.
Zitieren
APA
Rajni, E., Galav, H., & Bairwa, K. (2026). An insight into Ceftazidime-avibactam activity on Carbapenem-resistant Enterobacterales causing bloodstream infections. Journal of Research in Clinical Medicine, 14, 34779. https://doi.org/10.34172/jrcm.026.34799
Vancouver
Rajni E, Galav H, Bairwa K. An insight into Ceftazidime-avibactam activity on Carbapenem-resistant Enterobacterales causing bloodstream infections. Journal of Research in Clinical Medicine. 2026;14:34779. doi:10.34172/jrcm.026.34799
BibTeX
@article{Rajni2026,
author = {Rajni, Ekadashi and Galav, Himanshi and Bairwa, Kanika},
title = {An insight into Ceftazidime-avibactam activity on Carbapenem-resistant Enterobacterales causing bloodstream infections},
journal = {Journal of Research in Clinical Medicine},
year = {2026},
volume = {14},
pages = {34779},
doi = {10.34172/jrcm.026.34799}
}
EUVIMED